The de-SPAC provides substantial capital to advance Freenome's cancer screening pipeline and commercial partnerships. Traders should monitor upcoming clinical data readouts (PROACT Lung study) and commercial launch updates for the CRC test, as these will be key catalysts for the newly public stock.
Price Chart
Executive Summary
Freenome completed its de-SPAC merger with Perceptive Capital Solutions Corp, securing approximately $310 million in gross proceeds ($70M from trust + $240M PIPE) to fund its blood-based cancer screening pipeline. The combined company begins trading on Nasdaq under FRNM on July 21, 2026, with capital earmarked for scaling its AI-enabled multiomics platform and commercial infrastructure.
Key Financial Metrics
Key Facts
- Business combination with Perceptive Capital Solutions Corp closed; common stock to trade on Nasdaq under FRNM starting July 21, 2026.
- Gross proceeds of approximately $310 million: ~$70 million from PCSC trust account and $240 million PIPE led by Perceptive Advisors and RA Capital.
- PIPE included participation from ADAR1 Capital Management, Bain Capital Life Sciences, Farallon Capital Management and other healthcare investors.
- Proceeds will support development of colorectal cancer screening test (SimpleScreen CRC), lung cancer test, and pipeline of 10+ additional indications.
- Strategic partnerships with Abbott and Roche are in place for commercial distribution and workflow integration.
Financial Impact
Gross proceeds of approximately $310 million from trust and PIPE
Risk Factors
- Dilution from PIPE and SPAC sponsor shares may pressure near-term stock price.
- Execution risk in scaling commercial operations and achieving market adoption for blood-based screening tests.
- Regulatory and reimbursement uncertainties for multi-cancer screening tests beyond colorectal cancer.
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3330086 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 20, 2026 6d ago | 8-K | $14.06 $14.01 | ▼ −0.36% | ▼ −0.88% | $12.72 (−9.53%) |
Oct 15, 2026 11d ago | Press Release | $11.75 $12.57 | ▲ +6.98% | ▲ +6.56% | $12.72 (+8.26%) |
Aug 28, 2026 8w ago | EFFECT | $14.79 $14.79 | · 0.00% | ▲ +0.30% | $12.72 (−14.00%) |
Aug 18, 2026 9w ago | S-1 | $13.63 $13.51 | ▼ −0.88% | ▼ −0.04% | $12.72 (−6.68%) |
Jul 27, 2026 12w ago | 3 | $10.77 $10.06 | ▼ −6.59% | ▼ −5.05% | $12.72 (+18.11%) |
Jul 23, 2026 13w ago | 8-K | $11.24 $11.38 | ▲ +1.25% | ▲ +1.22% | $12.72 (+13.17%) |
Jul 20, 2026 14w ago | Press Release | $13.01 $13.14 | ▲ +1.00% | ▲ +1.12% | $12.72 (−2.23%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers